Renal Cell Carcinoma Patients      

FOI REFERENCE: 24173  FOI DATE: 14^th June 2024       

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage)

Avelumab + Axitinib -**

Axinitib – **

Cabozantinib –11Patients

Everolimus – 0 Patients

Lenvatinib + Everolimus – 0 Patients

Lenvatinib + Pembrolizumab –11Patients

Nivolumab monotherapy- 0 Patients

Nivolumab + Cabozantinib- 0 Patients

Nivolumab + Ipilimumab- 0 Patients

Pazopanib – 18 Patients

Pembrolizumab monotherapy-18 Patients

Pembrolizumab + Axitinib – 0 Patients

Radiotherapy only- 0 Patients

Sunitinib- **

Temsirolimus – 0 Patients

Tivozanib – 0 Patients

Other active systemic anti-cancer therapy – Cisplatin+Gemcitabine-11, Denosumab-7,Paclitaxel_Carboplatin-**

Palliative care only – 47 Patients

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? 12 Patients (Inpatient Data only)

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

Nivolumab (monotherapy) – 10 Patients

Nivolumab + Ipilimumab – 0 Patients

Nivolumab + Cabozantinib – 0 Patients

Lenvatinib + Pembrolizumab –11 Patients

Avelumab + Axitinib -**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

Worcestershire Acute Hospitals NHS Trust do not have any trials involving renal cell carcinoma at present. 

**This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018